Discovery Laboratories, Inc. (NASDAQ:DSCO)

CAPS Rating: 3 out of 5

A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.

Recs

3
Player Avatar rwpaules (95.82) Submitted: 9/9/2011 7:52:59 AM : Underperform Start Price: $2.25 DSCO Score: +28.78

After three FDA rejections on Surfaxin, I have little confidence that this company is even capable of bringing a product to market. The only thing they're discovering is how to squander shareholder value.

Report this Post 2 Replies
Member Avatar californiasun (61.35) Submitted: 9/24/2011 6:33:54 PM
Recs: 0

Seriously, I bailed on this company years ago on the "hopes" that they will get FDA approval. I feel sorry for anyone who gets their money locked in this company on a negative note. On the other hand, for those who invested in DSCO, best of luck! Hope your investment grows.

Member Avatar MrSinnister (< 20) Submitted: 6/11/2012 8:12:34 AM
Recs: 0

http://finance.yahoo.com/news/discovery-labs-present-afectair-data-114500983.html
http://www.russell.com/indexes/tools-resources/reconstitution/reconstitution-changes.asp

But this week has finally revealed the method to their madness as they were trying, with the 18 million shares released (it had already been planned at 2.8 b/f the runup after FDA approval of Surfaxin) to gain the capitalization to join the Russell 3000. They couldn't reveal this fact, or the short sellers would've swooped in like vultures trying to kill DSCO down sub 2's and their pricing, even with subsequent drops, still met the threshold after May 31 for market cap and liquidity, for entry. It hurt being a long in options, many expired, but you're about to see now volume, a nice run back up to 5 for the highs before the end of this month, and a very decent short squeeze this week. I think now is the best time to buy back in, as the entry is still going to be low, and the shorts will be scrambling to cover. If you're already still long, now it the time average down a bit and enjoy the run to 10 and beyond as Affectair could be sold in the EU as well as stateside, with both Surfaxin and Affectair being prepared to distribute by the last quarter. Good luck.

Featured Broker Partners


Advertisement